Synthetic DNA Technologies Enable Fast and Responsive SARS- CoV-2 Antibody Discovery and Optimization
Utilizing its proprietary DNA technology to write synthetic libraries, Twist Biopharma provides end-to-end antibody discovery and optimization solutions for the biotechnology industry.
This solution includes:
- Panel of highly diverse synthetic naïve antibody phage display libraries
- Several target class specific antibody phage display libraries against difficult-to-drug targets
- Twist Antibody Optimization (TAO) platform for antibody affinity and developability optimization
- High-throughput antibody expression service
To highlight the power of this platform, our anti-SARS-CoV-2 antibody discovery and optimization efforts will be presented. A panel of high affinity
anti-SARS-CoV-2 S1 and anti-ACE2 antibodies have been identified that may have both therapeutic and/or diagnostic applications.